clinical trial · NCT00692913
A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)
Organon and Co·phase3·completed·n = 515
OsteoporosisFOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)Calcium Supplement 500 mgReferred-Care Model
brief summary
A study designed to see if the study drug will increase blood levels of vitamin D, bone mineral density (BMD), improve biochemical markers of bone turnover, and reduce the number of falls as compared to women receiving standard care for osteoporosis.
started
Jun 1, 2008
primary completion
Jul 1, 2010
completion
Jul 1, 2010
last updated
May 9, 2024
official title
A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK -0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol